A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (Q37604531)
Jump to navigation
Jump to search
scientific article published on 28 August 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy |
scientific article published on 28 August 2015 |
Statements
1 reference
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (English)
1 reference
Jung-Yoon Choe
Nenad Prodanovic
Jaroslaw Niebrzydowski
Ivan Staykov
Eva Dokoupilova
Asta Baranauskaite
Mevludin Mekic
Wieskawa Porawska
Krystyna Jedrychowicz-Rosiak
Agnieszka Zielinska
Jasmine Choi
Young Hee Rho
28 August 2015
1 reference
1 reference
1 reference
1 reference